Investors

At NewzenPharma, we are redefining cancer treatment through targeted, innovative therapies that address unmet needs for patients worldwide. Founded on a foundation of rigorous scientific research and cutting-edge technology, NewzenPharma is committed to delivering therapies that improve both survival and quality of life.

Our lead programs, including Newzen-138, Newzen-150, and Newzen-170, leverage proprietary technologies and unique biological mechanisms to provide effective treatment options. Newzen-138, for example, targets the DNA repair machinery to inhibit cancer cell proliferation without harming healthy cells, positioning it as a game-changer in advanced cancer therapies. Meanwhile, our antibody-based project, Newzen-150, and our latest project, Newzen-170, represent the next steps in targeted oncology.

With a current market cap of $190 billion, NewzenPharma’s technologies are backed by patents and a proven proof of concept. We are in a Series A funding round with a pre-money valuation of $500 million and invite investors who are passionate about advancing cancer treatment to join us in driving this mission forward.